TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Dyne Therapeutics Stock Crushed the Market on Monday

The Motley Fool Logo The Motley Fool By Eric Volkman
Why Dyne Therapeutics Stock Crushed the Market on Monday

Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.

Insights
DYN   positive

Stock price increased significantly due to market speculation about potential future acquisition based on similar company's premium buyout